# EDGAR Filing Document

**Accession Number:** 0001100663
**File Stem:** 0001410368-25-043365
**Filing Date:** 2025-12
**Character Count:** 38017
**Document Hash:** 8037c2933caa3ed86c5e34c8a470988b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001410368-25-043365.hdr.sgml**: 20251229

**ACCESSION NUMBER**: 0001410368-25-043365

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251031

**FILED AS OF DATE**: 20251229

**DATE AS OF CHANGE**: 20251229

**PERIOD START**: 20260731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iSHARES TRUST
- **CENTRAL INDEX KEY:** 0001100663

**ORGANIZATION NAME:**
- **EIN:** 943351276
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-09729
- **FILM NUMBER:** 251606760

**BUSINESS ADDRESS:**
- **STREET 1:** 400 HOWARD STREET
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94105
- **BUSINESS PHONE:** (415) 670-2000

**MAIL ADDRESS:**
- **STREET 1:** 400 HOWARD STREET
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94105

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ISHARES TRUST
- **DATE OF NAME CHANGE:** 19991213

## Series and Classes Contracts Data

### iShares Neuroscience and Healthcare ETF (Series ID: S000076483)

| Class ID   | Class Name                              | Ticker Symbol   |
|:---|:---|:---|
| C000236410 | iShares Neuroscience and Healthcare ETF | IBRN            |

## Nport-Ex

Schedule of Investments (unaudited)

October 31, 2025

**iShares® Neuroscience and Healthcare ETF**

**(Percentages shown are based on Net Assets)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
| *Security* | &nbsp;&nbsp; *Shares* | *Value* |
| **Common Stocks** | **Common Stocks** | **Common Stocks** |
| **Biotechnology — 68.1%** | **Biotechnology — 68.1%** | **Biotechnology — 68.1%** |
| Acadia Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 6145 | $139491 |
| Alector Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 5082 | 7471 |
| Alkermes PLC<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 5186 | 159210 |
| Anavex Life Sciences Corp.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 5535 | 44114 |
| Annexon Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 6379 | 20158 |
| Argenx SE, ADR<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 207 | 169429 |
| Benitec Biopharma Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 1637 | 26781 |
| BioArctic AB, Class B<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 2662 | 82156 |
| Biogen Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 1104 | 170314 |
| Biohaven Ltd.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 6159 | 105935 |
| Bright Minds Biosciences Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 472 | 25842 |
| Capricor Therapeutics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 2677 | 17427 |
| Catalyst Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 7485 | 159206 |
| Centessa Pharmaceuticals PLC, ADR<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 5727 | 142602 |
| Denali Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 8513 | 138592 |
| Dianthus Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1565 | 54744 |
| Dyne Therapeutics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 7386 | 166776 |
| Entrada Therapeutics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 1495 | 10390 |
| Idorsia Ltd.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 10322 | 45000 |
| Larimar Therapeutics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 3304 | 12853 |
| Neurocrine Biosciences Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1077 | 154237 |
| Neurogene Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 804 | 27545 |
| Oncolys BioPharma Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1600 | 7774 |
| Praxis Precision Medicines Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 1324 | 263158 |
| Prothena Corp. PLC<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 2898 | 31153 |
| PTC Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 2710 | 185120 |
| REGENXBIO Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 3053 | 38987 |
| SanBio Co. Ltd.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 3500 | 64188 |
| Sangamo Therapeutics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 19103 | 11424 |
| Sarepta Therapeutics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 6253 | 150135 |
| Scholar Rock Holding Corp.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 4942 | 146382 |
| Solid Biosciences Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 3889 | 20962 |
| Taysha Gene Therapies Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 14820 | 73507 |
| Tonix Pharmaceuticals Holding Corp.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 584 | 10874 |
| Vanda Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 3668 | 15956 |
| Voyager Therapeutics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 3021 | 14108 |
| Xenon Pharmaceuticals Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 3960 | 166003 |
|  |  | 3080004 |
| **Health Care Equipment & Supplies — 6.3%** | **Health Care Equipment & Supplies — 6.3%** | **Health Care Equipment & Supplies — 6.3%** |
| Axogen Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 2961 | 65793 |
| Ceribell Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1354 | 15436 |
| ClearPoint Neuro Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 1623 | 37686 |
| Integra LifeSciences Holdings Corp.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 4388 | 52700 |
| MicroPort NeuroScientific Corp. | &nbsp;&nbsp;&nbsp; 16000 | 24307 |
| Neuronetics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 2686 | 7118 |
| NeuroPace Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1571 | 15616 |

---

---

| | | |
|:---|:---|:---|
| *Security* | &nbsp;&nbsp; *Shares* | *Value* |
| **Health Care Equipment & Supplies (continued)** | **Health Care Equipment & Supplies (continued)** | **Health Care Equipment & Supplies (continued)** |
| Peijia Medical Ltd.<sup>(a)(c)</sup> | &nbsp;&nbsp;&nbsp; 31000 | $23999 |
| &nbsp;&nbsp;&nbsp; Shanghai HeartCare Medical Technology Corp. Ltd., <br> Class H<sup>(a)(c)</sup><br>| &nbsp;&nbsp;&nbsp; 1100 | 7762 |
| Zylox-Tonbridge Medical Technology Co. Ltd., Class H<sup>(c)</sup> | &nbsp;&nbsp;&nbsp; 12000 | 36466 |
|  |  | 286883 |
| **Pharmaceuticals — 24.0%** | **Pharmaceuticals — 24.0%** | **Pharmaceuticals — 24.0%** |
| Avadel Pharmaceuticals PLC<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 5991 | 113170 |
| Axsome Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1241 | 167523 |
| Cassava Sciences Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 2799 | 9125 |
| Cognition Therapeutics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 4727 | 8461 |
| Edgewise Therapeutics Inc.<sup>(a)(b)</sup> | &nbsp;&nbsp;&nbsp; 5042 | 92168 |
| Fulcrum Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 3197 | 27974 |
| H Lundbeck A/S | &nbsp;&nbsp;&nbsp; 17826 | 130007 |
| Medincell SA, NVS<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1367 | 60653 |
| Neuren Pharmaceuticals Ltd.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 7165 | 101707 |
| Rapport Therapeutics Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1164 | 33674 |
| SK Biopharmaceuticals Co. Ltd.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 1884 | 152334 |
| Supernus Pharmaceuticals Inc.<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 3374 | 186009 |
|  |  | 1082805 |
| **Technology Hardware, Storage & Peripherals — 1.5%** | **Technology Hardware, Storage & Peripherals — 1.5%** | **Technology Hardware, Storage & Peripherals — 1.5%** |
| Dynavox Group AB<sup>(a)</sup> | &nbsp;&nbsp;&nbsp; 6453 | 66394 |
| **Total Long-Term Investments — 99.9%** <br>**(Cost: $3,555,029)** | **Total Long-Term Investments — 99.9%** <br>**(Cost: $3,555,029)** | 4516086 |
| **Short-Term Securities** | **Short-Term Securities** | **Short-Term Securities** |
| **Money Market Funds — 32.8%** | **Money Market Funds — 32.8%** | **Money Market Funds — 32.8%** |
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Institutional, SL Agency Shares, <br> 4.27%<sup>(d)(e)(f)</sup><br>| &nbsp;&nbsp;&nbsp; 1483687 | 1484428 |
| **Total Short-Term Securities — 32.8%** <br>**(Cost: $1,484,362)** | **Total Short-Term Securities — 32.8%** <br>**(Cost: $1,484,362)** | 1484428 |
| **Total Investments — 132.7%** <br>**(Cost: $5,039,391)** | **Total Investments — 132.7%** <br>**(Cost: $5,039,391)** | 6000514 |
| **Liabilities in Excess of Other Assets — (32.7)%** | **Liabilities in Excess of Other Assets — (32.7)%** | (1479026)<br>|
| **Net Assets — 100.0%** | **Net Assets — 100.0%** | $4521488 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> All or a portion of this security is on loan.

<sup>(c)</sup> Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors. 

<sup>(d)</sup> Affiliate of the Fund.

<sup>(e)</sup> Annualized 7-day yield as of period end.

<sup>(f)</sup> All or a portion of this security was purchased with the cash collateral from loaned securities. 

------

Schedule of Investments (unaudited)(continued)

October 31, 2025

**iShares® Neuroscience and Healthcare ETF**

**Affiliates**

Investments in issuers considered to be affiliate(s) of the Fund during the period ended October 31, 2025 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| *Affiliated Issuer* | *Value at* <br>*07/31/25*<br>| &nbsp;&nbsp; *Proceeds* <br>*from Sales*<br>| *Net Realized* <br>*Gain (Loss)*<br>| *Change in* <br>*Unrealized* <br>*Appreciation* <br>*(Depreciation)*<br>| *Value at* <br>*10/31/25*<br>| *Shares* <br>*Held at* <br>*10/31/25*<br>| *Income* | &nbsp;&nbsp; *Capital* <br>*Gain* <br>*Distributions* <br>*from* <br>*Underlying* <br>*Funds*<br>|
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Institutional, SL Agency <br> Shares<br>| $1146198<br> $338086 <br><sup>(a)</sup><br>| $— | $113 | $31 | $1484428 | 1483687 | $2878 <br><sup>(b)</sup><br>| $— |
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Treasury, SL Agency <br> Shares<sup>(c)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; —<br> 0 <br><sup>(a)</sup><br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; — |
|  |  |  | $113 | $31 | $1484428 |  | $2884 | $— |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Represents net amount purchased (sold).

<sup>(b)</sup> All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and other payments to and from borrowers of securities. 

<sup>(c)</sup> As of period end, the entity is no longer held.

**Fair Value Hierarchy as of Period End** 

Various inputs are used in determining the fair value of financial instruments at the measurement date. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:

• Level 1 – Unadjusted price quotations in active markets/exchanges that the Fund has the ability to access for identical assets or liabilities;

• Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3 – Inputs that are unobservable and significant to the entire fair value measurement for the asset or liability (including the Valuation Committee's assumptions used in determining the fair value of financial instruments).

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds that may not have a secondary market and/or may have a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Fund's policy regarding valuation of financial instruments, refer to its most recent financial statements.

The following table summarizes the Fund's financial instruments categorized in the fair value hierarchy. The breakdown of the Fund's financial instruments into major categories is disclosed in the Schedule of Investments above.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Level 1* | *Level 2* | *Level 3* | *Total* |
| Assets  |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Investments  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-Term Investments  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common Stocks | &nbsp;&nbsp; $3713339 | &nbsp;&nbsp; $802747 | &nbsp;&nbsp; $— | &nbsp;&nbsp; $4516086 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short-Term Securities  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Money Market Funds | &nbsp;&nbsp; 1484428 | &nbsp;&nbsp; — | &nbsp;&nbsp; — | &nbsp;&nbsp; 1484428 |
|  | &nbsp;&nbsp; $5197767 | &nbsp;&nbsp; $802747 | &nbsp;&nbsp; $— | &nbsp;&nbsp; $6000514 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| **Portfolio Abbreviation** | **Portfolio Abbreviation** |
| ADR | American Depositary Receipt |
| NVS | Non-Voting Shares |

---

------

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** iShares Trust

- **b. Investment Company Act file number:** 811-09729

- **c. CIK number of Registrant:** 0001100663

- **d. LEI of Registrant:** 5493000860OXIC4B5K91

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 400 Howard Street

  - **City:** San Francisco

  - **State:** CA

  - **Foreign country:** US

  - **Zip / Postal Code:** 94105

  - **Telephone number:** 800-474-2737

**Item A.2. Information about the Series.**

- **a. Name of Series:** iShares Neuroscience and Healthcare ETF

- **b. EDGAR series identifier (if any):** S000076483

- **c. LEI of Series:** 549300JGI839T0141L50

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-07-31

- **b. Date as of which information is reported:** 2025-10-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $7787831.29

**Total Liabilities:** $3266427.08

**Net Assets:** $4521404.21

**Cash Not Reported:** $5770.50

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000236410 | 7.10%                | 7.36%                | 12.39%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $59.98                   | $248629.49                                 |
| Month 2  | $-72498.99               | $348347.68                                 |
| Month 3  | $6.20                    | $499161.98                                 |

### Schedule of Portfolio Investments

| Name                                           | Title                                                 | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| ACADIA Pharmaceuticals Inc                     | ACADIA Pharmaceuticals Inc                            | CUSIP: 004225108<br>LEI: 529900O3044NO0PEA039 | Long             | EC               | CORP              | US        |      6145 | NS      | $139491.50    | 3.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Alector Inc                                    | Alector Inc                                           | CUSIP: 014442107<br>LEI: 549300Z8RQOIY1JMHC25 | Long             | EC               | CORP              | US        |      5082 | NS      | $7470.54      | 0.17%             |  |  |  | No            |                  1 | On Loan: No      |
| Anavex Life Sciences Corp                      | Anavex Life Sciences Corp                             | CUSIP: 032797300<br>LEI: 549300K1I5L8COCQ8W36 | Long             | EC               | CORP              | US        |      5535 | NS      | $44113.95     | 0.98%             |  |  |  | No            |                  1 | On Loan: —       |
| Annexon Inc                                    | Annexon Inc                                           | CUSIP: 03589W102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      6379 | NS      | $20157.64     | 0.45%             |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                                      | Argenx SE                                             | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |       207 | NS      | $169429.50    | 3.75%             |  |  |  | No            |                  1 | On Loan: No      |
| Axogen Inc                                     | Axogen Inc                                            | CUSIP: 05463X106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      2961 | NS      | $65793.42     | 1.46%             |  |  |  | No            |                  1 | On Loan: —       |
| Axsome Therapeutics Inc                        | Axsome Therapeutics Inc                               | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |      1241 | NS      | $167522.59    | 3.71%             |  |  |  | No            |                  1 | On Loan: No      |
| Benitec Biopharma Inc                          | Benitec Biopharma Inc                                 | CUSIP: 08205P209<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1637 | NS      | $26781.32     | 0.59%             |  |  |  | No            |                  1 | On Loan: —       |
| Biogen Inc                                     | Biogen Inc                                            | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |      1104 | NS      | $170314.08    | 3.77%             |  |  |  | No            |                  1 | On Loan: —       |
| Bright Minds Biosciences Inc                   | Bright Minds Biosciences Inc                          | CUSIP: 10919W405<br>LEI: N/A                  | Long             | EC               | CORP              | CA        |       472 | NS      | $25842.00     | 0.57%             |  |  |  | No            |                  1 | On Loan: No      |
| Capricor Therapeutics Inc                      | Capricor Therapeutics Inc                             | CUSIP: 14070B309<br>LEI: 5493002ZI5PDLXV4DX14 | Long             | EC               | CORP              | US        |      2677 | NS      | $17427.27     | 0.39%             |  |  |  | No            |                  1 | On Loan: —       |
| Cassava Sciences Inc                           | Cassava Sciences Inc                                  | CUSIP: 14817C107<br>LEI: 529900XA0UG5JXABYF08 | Long             | EC               | CORP              | US        |      2799 | NS      | $9124.74      | 0.20%             |  |  |  | No            |                  1 | On Loan: —       |
| Catalyst Pharmaceuticals Inc                   | Catalyst Pharmaceuticals Inc                          | CUSIP: 14888U101<br>LEI: 5299004O0R5XXLA5H544 | Long             | EC               | CORP              | US        |      7485 | NS      | $159205.95    | 3.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Centessa Pharmaceuticals PLC                   | Centessa Pharmaceuticals PLC                          | CUSIP: 152309100<br>LEI: 213800GIDAARDSKOI827 | Long             | EC               | CORP              | GB        |      5727 | NS      | $142602.30    | 3.15%             |  |  |  | No            |                  1 | On Loan: No      |
| Ceribell Inc                                   | Ceribell Inc                                          | CUSIP: 15678C102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1354 | NS      | $15435.60     | 0.34%             |  |  |  | No            |                  1 | On Loan: No      |
| ClearPoint Neuro Inc                           | ClearPoint Neuro Inc                                  | CUSIP: 18507C103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1623 | NS      | $37686.06     | 0.83%             |  |  |  | No            |                  1 | On Loan: —       |
| Cognition Therapeutics Inc                     | Cognition Therapeutics Inc                            | CUSIP: 19243B102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      4727 | NS      | $8461.33      | 0.19%             |  |  |  | No            |                  1 | On Loan: —       |
| Denali Therapeutics Inc                        | Denali Therapeutics Inc                               | CUSIP: 24823R105<br>LEI: 549300ZTQ2HO18L3Q830 | Long             | EC               | CORP              | US        |      8513 | NS      | $138591.64    | 3.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Dianthus Therapeutics Inc                      | Dianthus Therapeutics Inc                             | CUSIP: 252828108<br>LEI: 549300Z3N6ODPCOFC890 | Long             | EC               | CORP              | US        |      1565 | NS      | $54743.70     | 1.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Dyne Therapeutics Inc                          | Dyne Therapeutics Inc                                 | CUSIP: 26818M108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      7386 | NS      | $166775.88    | 3.69%             |  |  |  | No            |                  1 | On Loan: —       |
| Edgewise Therapeutics Inc                      | Edgewise Therapeutics Inc                             | CUSIP: 28036F105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      5042 | NS      | $92167.76     | 2.04%             |  |  |  | No            |                  1 | On Loan: —       |
| Entrada Therapeutics Inc                       | Entrada Therapeutics Inc                              | CUSIP: 29384C108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1495 | NS      | $10390.25     | 0.23%             |  |  |  | No            |                  1 | On Loan: —       |
| Fulcrum Therapeutics Inc                       | Fulcrum Therapeutics Inc                              | CUSIP: 359616109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      3197 | NS      | $27973.75     | 0.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Integra LifeSciences Holdings Corp             | Integra LifeSciences Holdings Corp                    | CUSIP: 457985208<br>LEI: WB7IJCYY8YFTENS4O147 | Long             | EC               | CORP              | US        |      4388 | NS      | $52699.88     | 1.17%             |  |  |  | No            |                  1 | On Loan: No      |
| Larimar Therapeutics Inc                       | Larimar Therapeutics Inc                              | CUSIP: 517125100<br>LEI: 529900NCBZHTTJV6HX73 | Long             | EC               | CORP              | US        |      3304 | NS      | $12852.56     | 0.28%             |  |  |  | No            |                  1 | On Loan: —       |
| Neurocrine Biosciences Inc                     | Neurocrine Biosciences Inc                            | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |      1077 | NS      | $154237.17    | 3.41%             |  |  |  | No            |                  1 | On Loan: No      |
| NeuroPace Inc                                  | NeuroPace Inc                                         | CUSIP: 641288105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1571 | NS      | $15615.74     | 0.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Neuronetics Inc                                | Neuronetics Inc                                       | CUSIP: 64131A105<br>LEI: 549300T0911ILTTG7P06 | Long             | EC               | CORP              | US        |      2686 | NS      | $7117.90      | 0.16%             |  |  |  | No            |                  1 | On Loan: —       |
| Neurogene Inc                                  | Neurogene Inc                                         | CUSIP: 64135M105<br>LEI: 529900A7VIY892SZVW73 | Long             | EC               | CORP              | US        |       804 | NS      | $27545.04     | 0.61%             |  |  |  | No            |                  1 | On Loan: —       |
| PTC Therapeutics Inc                           | PTC Therapeutics Inc                                  | CUSIP: 69366J200<br>LEI: 549300UJLWOIWFDGB318 | Long             | EC               | CORP              | US        |      2710 | NS      | $185120.10    | 4.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Praxis Precision Medicines Inc                 | Praxis Precision Medicines Inc                        | CUSIP: 74006W207<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1324 | NS      | $263158.24    | 5.82%             |  |  |  | No            |                  1 | On Loan: —       |
| Rapport Therapeutics Inc                       | Rapport Therapeutics Inc                              | CUSIP: 75383L102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1164 | NS      | $33674.52     | 0.74%             |  |  |  | No            |                  1 | On Loan: No      |
| REGENXBIO Inc                                  | REGENXBIO Inc                                         | CUSIP: 75901B107<br>LEI: 549300EOES47LATSET33 | Long             | EC               | CORP              | US        |      3053 | NS      | $38986.81     | 0.86%             |  |  |  | No            |                  1 | On Loan: No      |
| Sangamo Therapeutics Inc                       | Sangamo Therapeutics Inc                              | CUSIP: 800677106<br>LEI: 2549006WMRKRC4G32Z67 | Long             | EC               | CORP              | US        |     19103 | NS      | $11423.59     | 0.25%             |  |  |  | No            |                  1 | On Loan: —       |
| Sarepta Therapeutics Inc                       | Sarepta Therapeutics Inc                              | CUSIP: 803607100<br>LEI: 549300IKDPIED8J8IG21 | Long             | EC               | CORP              | US        |      6253 | NS      | $150134.53    | 3.32%             |  |  |  | No            |                  1 | On Loan: —       |
| Scholar Rock Holding Corp                      | Scholar Rock Holding Corp                             | CUSIP: 80706P103<br>LEI: 549300Z1FLPGL4OWJ459 | Long             | EC               | CORP              | US        |      4942 | NS      | $146382.04    | 3.24%             |  |  |  | No            |                  1 | On Loan: —       |
| Solid Biosciences Inc                          | Solid Biosciences Inc                                 | CUSIP: 83422E204<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      3889 | NS      | $20961.71     | 0.46%             |  |  |  | No            |                  1 | On Loan: No      |
| Supernus Pharmaceuticals Inc                   | Supernus Pharmaceuticals Inc                          | CUSIP: 868459108<br>LEI: 549300GRM36VBKISYJ58 | Long             | EC               | CORP              | US        |      3374 | NS      | $186008.62    | 4.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Taysha Gene Therapies Inc                      | Taysha Gene Therapies Inc                             | CUSIP: 877619106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     14820 | NS      | $73507.20     | 1.63%             |  |  |  | No            |                  1 | On Loan: —       |
| Tonix Pharmaceuticals Holding Corp             | Tonix Pharmaceuticals Holding Corp                    | CUSIP: 890260839<br>LEI: 529900ACPKP9QW20GX48 | Long             | EC               | CORP              | US        |       584 | NS      | $10874.08     | 0.24%             |  |  |  | No            |                  1 | On Loan: —       |
| Vanda Pharmaceuticals Inc                      | Vanda Pharmaceuticals Inc                             | CUSIP: 921659108<br>LEI: 529900AY8VOOQBKJ0O70 | Long             | EC               | CORP              | US        |      3668 | NS      | $15955.80     | 0.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Voyager Therapeutics Inc                       | Voyager Therapeutics Inc                              | CUSIP: 92915B106<br>LEI: 54930082S4XVR0ZWCC74 | Long             | EC               | CORP              | US        |      3021 | NS      | $14108.07     | 0.31%             |  |  |  | No            |                  1 | On Loan: —       |
| BlackRock Funds III                            | BlackRock Cash Funds: Institutional, SL Agency Shares | CUSIP: 066922519<br>LEI: 5493008LW2651I1QB503 | Long             | STIV             | RF                | US        |   1630858 | NS      | $1631673.65   | 36.09%            |  |  |  | No            |                  1 | On Loan: No      |
| Xenon Pharmaceuticals Inc                      | Xenon Pharmaceuticals Inc                             | CUSIP: 98420N105<br>LEI: 549300XV44Q9Z1MIPQ03 | Long             | EC               | CORP              | CA        |      3960 | NS      | $166003.20    | 3.67%             |  |  |  | No            |                  1 | On Loan: —       |
| SK Biopharmaceuticals Co Ltd                   | SK Biopharmaceuticals Co Ltd                          | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | KR        |      1884 | NS      | $152334.53    | 3.37%             |  |  |  | No            |                  2 | On Loan: No      |
| Dynavox Group AB                               | Dynavox Group AB                                      | CUSIP: 000000000<br>LEI: 5493008X1XZR4R5R0P66 | Long             | EC               | CORP              | SE        |      6453 | NS      | $66394.01     | 1.47%             |  |  |  | No            |                  2 | On Loan: No      |
| MicroPort NeuroScientific Corp                 | MicroPort NeuroScientific Corp                        | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | KY        |     16000 | NS      | $24307.15     | 0.54%             |  |  |  | No            |                  2 | On Loan: No      |
| Medincell SA                                   | Medincell SA                                          | CUSIP: 000000000<br>LEI: 969500R79U6PXCL2FF46 | Long             | EC               | CORP              | FR        |      1367 | NS      | $60652.85     | 1.34%             |  |  |  | No            |                  2 | On Loan: No      |
| Neuren Pharmaceuticals Ltd                     | Neuren Pharmaceuticals Ltd                            | CUSIP: 000000000<br>LEI: 984500E48D0FDEE7CE63 | Long             | EC               | CORP              | NZ        |      7165 | NS      | $101707.05    | 2.25%             |  |  |  | No            |                  2 | On Loan: No      |
| BioArctic AB                                   | BioArctic AB                                          | CUSIP: 000000000<br>LEI: 549300Y0OI2WVUNHLC33 | Long             | EC               | CORP              | SE        |      2662 | NS      | $82155.55     | 1.82%             |  |  |  | No            |                  2 | On Loan: No      |
| Idorsia Ltd                                    | Idorsia Ltd                                           | CUSIP: 000000000<br>LEI: 506700XOVZUB107S5720 | Long             | EC               | CORP              | CH        |     10322 | NS      | $44999.84     | 1.00%             |  |  |  | No            |                  2 | On Loan: No      |
| Oncolys BioPharma Inc                          | Oncolys BioPharma Inc                                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | JP        |      1600 | NS      | $7773.65      | 0.17%             |  |  |  | No            |                  2 | On Loan: No      |
| H Lundbeck A/S                                 | H Lundbeck A/S                                        | CUSIP: 000000000<br>LEI: 5493006R4KC2OI5D3470 | Long             | EC               | CORP              | DK        |     17826 | NS      | $130007.42    | 2.88%             |  |  |  | No            |                  2 | On Loan: No      |
| Peijia Medical Ltd                             | Peijia Medical Ltd                                    | CUSIP: 000000000<br>LEI: 300300VE46IBS1WO9M65 | Long             | EC               | CORP              | KY        |     31000 | NS      | $23998.62     | 0.53%             |  |  |  | No            |                  2 | On Loan: No      |
| Shanghai HeartCare Medical Technology Corp Ltd | Shanghai HeartCare Medical Technology Corp Ltd        | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | CN        |      1100 | NS      | $7762.26      | 0.17%             |  |  |  | No            |                  2 | On Loan: No      |
| Zylox-Tonbridge Medical Technology Co Ltd      | Zylox-Tonbridge Medical Technology Co Ltd             | CUSIP: 000000000<br>LEI: 254900QSIU3I0P3OEJ92 | Long             | EC               | CORP              | CN        |     12000 | NS      | $36466.27     | 0.81%             |  |  |  | No            |                  2 | On Loan: No      |
| SanBio Co Ltd                                  | SanBio Co Ltd                                         | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | JP        |      3500 | NS      | $64188.27     | 1.42%             |  |  |  | No            |                  2 | On Loan: —       |
| Alkermes PLC                                   | Alkermes PLC                                          | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | IE        |      5186 | NS      | $159210.20    | 3.52%             |  |  |  | No            |                  1 | On Loan: —       |
| Biohaven Ltd                                   | Biohaven Ltd                                          | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | VG        |      6159 | NS      | $105934.80    | 2.34%             |  |  |  | No            |                  1 | On Loan: No      |
| Avadel Pharmaceuticals PLC                     | Avadel Pharmaceuticals PLC                            | CUSIP: 000000000<br>LEI: 549300E27PTSG2RHC762 | Long             | EC               | CORP              | IE        |      5991 | NS      | $113169.99    | 2.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Prothena Corp PLC                              | Prothena Corp PLC                                     | CUSIP: 000000000<br>LEI: 5299009ZXQ8NIIJ8OL30 | Long             | EC               | CORP              | IE        |      2898 | NS      | $31153.50     | 0.69%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-11-28

**Name of Applicant:** iShares Trust

**Signature:** Chuck Pulsfort

**Name of Signer:** Chuck Pulsfort

**Title:** Assistant Treasurer